lenalidomide has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilge, SS; Cankara, FN; Günaydın, C; Kortholt, A; Özmen, Ö | 1 |
| Argente-Escrig, H; Balaguer, A; Bataller, L; Gómez, E; Martinez, JC; Sevilla, T | 1 |
2 other study(ies) available for lenalidomide and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
The neuroprotective action of lenalidomide on rotenone model of Parkinson's Disease: Neurotrophic and supportive actions in the substantia nigra pars compacta.
Topics: Animals; Brain-Derived Neurotrophic Factor; Calcium-Binding Proteins; Caspase 9; Cell Survival; Dopamine; Dopaminergic Neurons; Lenalidomide; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Pars Compacta; Rats; Rotenone; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2020 |
Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease.
Topics: Angiogenesis Inhibitors; Brain; Creutzfeldt-Jakob Syndrome; Dementia; Dystonia; Fatal Outcome; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Parkinsonian Disorders | 2018 |